Naltrexone hydrochloride is a synthetic opioid receptor antagonist recently used in efforts to provide rapid opioid detoxification. Other clinical uses include alleviating itch due to cholestasis or uraemia. We report a case where unrecognised naltrexone therapy for itch affected anaesthesia, resulting in high opioid requirements. We also discuss other analgesic options utilized.
Naltrexone hydrochloride is a long-acting, pure opioid competitive antagonist closely related to naloxone. A synthetic analogue of oxymorphone, naltrexone has been available since 1965, and naloxone since 1961. In subjects who are physically dependent on opioids, oral naltrexone can precipitate withdrawal symptomatology within five minutes.
CASE REPORT
A 72-year-old 50 kg woman presented for revision of a proximal forearm A-V fistula and debridement of a heel ulcer. Her medical history included non-insulin dependent diabetes mellitus with associated nephropathy, retinopathy and cataracts. She had secondary hyperparathyroidism and she was soon to commence dialysis. She also had peripheral vascular disease, hypertension, hypothyroidism, mild chronic airways limitation, an atrial septal defect with mild pulmonary hypertension and peptic ulcer disease. Her medications were thyroxine 100 µg daily, glicazide 160 mg bd, hydroxyzine 50 mg nocte, methdilazine 8 mg bd, lisinopril 20 mg mane, felodipine SR 5 mg daily, calcium carbonate 1.5 g bd, erythropoietin 4000 units twice weekly, sodium bicarbonate 840 mg tds, frusemide 40 mg bd and calcitriol 2 µg weekly.
There was reasonable control of her medical problems. Previous general anaesthesia for cataract extraction had been uneventful, except for some postoperative nausea. She requested a general anaesthetic on the present occasion and was monitored with an AS-3 integrated system (Datex, Helsinki, Finland). Prior to induction her noninvasive blood pressure (NIBP) was 120/60 mmHg and pulse rate 70 bpm. Anaesthesia was established with alfentanil 1 mg and propofol. Propofol was delivered via a Diprifusor TCI (Graseby 3500, Herts, U.K.) set initially to a target concentration of 4 µg/ml. Oxygen 100% was delivered by mask ventilation and cisatracurium 7 mg was given to facilitate endotracheal intubation. This was accomplished at five minutes with a size 8 endotracheal tube and was associated with a large sympathetic response (pulse rate of 130 bpm, systolic NIBP 200 to 210 mmHg) which persisted despite bolus doses of alfentanil to a dose of 3 mg and an increase in the propofol target concentration to 5 µg/ml. Two bolus doses of hydralazine 2 mg were given, bringing the systolic NIBP down to 170 mmHg.
On reviewing her medication chart it was noted that her morning antihypertensive medications had been withheld despite standing orders. It was also then noted naltrexone 50 mg orally daily had been charted in the variable dose section for the previous six days. The morning dose had been withheld. There was no apparent reason for this from the notes or history, but it helped explain the lack of response to alfentanil.
Subsequently, other analgesic methods were considered. Ketamine was unfortunately not immediately available. The forearm dissection was infiltrated with local anaesthetic (bupivacaine 0.25% 15 ml). A remifentanil infusion (50 µg/ml) was commenced, initially at 0.7 µg/kg/min, then increased to 1.4, then 1.7 µg/kg/min. Heart rate and blood pressure gradually settled to acceptable levels. The propofol target concentration was reduced to 4 µg/ml. A left anterior sciatic nerve block (as described by Labat 1 ) was inserted prior to debridement of the heel, and ketamine bolus doses of 10 mg up to 40 mg IV were given when it became available. The remifentanil infusion could be then reduced gradually to 0.5 µg/kg/min and ceased five minutes before extubation.
The patient was initially drowsy, but rapidly improved. No further analgesia was required in the recovery room or the ward and there was no recall of events. The naltrexone had been prescribed for intractable uraemic itch, although it had not been helpful in relieving her symptoms.
DISCUSSION
Naltrexone HCl 50 mg tablets are well absorbed orally but significant first pass metabolism means bioavailability varies between 5 and 40%. Volume of distribution of naltrexone is large (1350 l) with 21% protein binding. A daily dosage of 50 mg is more than adequate to saturate opioid receptors 2 . Naltrexone is more than 98% metabolized, mainly to 6-beta naltrexol. Both are primarily renally excreted with the mean elimination T 1 ¼2 value for naltrexone four hours and the metabolite 13 hours. However, the half-time for the terminal phase of naltrexone clearance is 96 hours 2 and this longer timeframe is consistent with the duration of pharmacological effects of naltrexone in response to heroin administration 2 and the duration of brain mu-receptor occupancy by naltrexone as measured by positron radiation detection of agonists at defined time intervals 3 . It may be this last factor which is relevant to anaesthesia timing.
Cumulation in doses up to 200 mg per day does not occur, but adequate studies of naltrexone in patients with severe hepatic or renal impairment have not been conducted. There is an increased risk of hepatocellular injury associated with dosages greater than 50 mg daily and a recent case report attributed rhabdomyolysis to naltrexone therapy 4 .
Common clinical uses for naltrexone are the maintenance of abstinence from opioids 5 and from alcohol 6 , and in opioid detoxification under anaesthesia 5 . In autism a reduction of hyperactivity, inattention and aggression has been shown 7 . In small doses naltrexone may reduce the risks of respiratory depression, pruritus and vomiting associated with epidural 8 and intrathecal 9 opiates. Its use as an antipruritic in cholestatic liver disease 10 and uraemia 11 imply that endogenous opioids are involved in this itch. Naltrexone has been shown to have shortterm efficacy with few side-effects. Itching is usually not completely abolished due to contributing nonopioid mechanisms, so is often combined with other antipruritic treatments such as antihistamines, steroid creams and cooling devices.
Patients on naltrexone therapy may present a challenge in anaesthesia and pain management as opioids in the usual doses are ineffective.
In an emergency situation, suggested options include local anaesthetic techniques, use of nonopioid analgesics, non-opioid sedation or general anaesthesia. Local anaesthetic conduction blockade is unaffected by opioid antagonists. Non-opioid analgesics include non-steroidal anti-inflammatory drugs (NSAIDs), ketamine and inhaled agents such as methoxyflurane or nitrous oxide. Naloxone has been shown to partially antagonize ketamine and nitrous oxide analgesia. The analgesic response of the NSAID ibuprofen has been shown to be unaffected by naltrexone compared with codeine or placebo 12 . The MAC of potent volatile anaesthetics is unaffected by naloxone and probably also by naltrexone.
Administration of high-dose opioids in an attempt to overcome naltrexone competitive blockade can result in bradycardia, chest wall rigidity and also histamine release with facial swelling, itching, generalized erythema and bronchoconstriction. An ultra-short-acting opioid analgesic which minimizes the duration of respiratory depression is preferred, for example, remifentanil. Non-urgent surgery may need to be delayed for up to 72 hours to allow for the long terminal elimination half-life of naltrexone. A longer delay may be required with renally impaired patients.
Of significant concern is the possibility of upregulation of opioid receptors following chronic naltrexone therapy, as this would place such subjects at increased risk of overdose, either with illicit narcotics or with therapeutic needs. One study with mice suggested that supersensitivity occurs for a broad range of opioid analgesics following chronic antagonist treatment 13 . A human study which investigated pain tolerance in opioid addicts on and off naltrexone therapy suggested that there may be upregulation in the presence of naltrexone 14 .
In our case the naltrexone therapy was unknown to the surgeon, not thought significant by the patient, not communicated by the medical team and missed by the anaesthetic team until intraoperative sympathetic responses provoked further investigation. In this patient NSAIDs were contraindicated and 702 alternative opioids in the high doses required may have had a prolonged duration of action. A deeper level of propofol anaesthesia may have been appropriate to attempt. A high titrated dose of remifentanil was an ideal agent, in combination with local anaesthetic techniques and non-opioid analgesics.
With the renewed interest in naltrexone in a number of specialties, the anaesthetist needs to have an understanding of the impact of this on his or her practice and have alternatives available.
